{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:18Z","timestamp":1792787838793,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the National Natural Science Foundation of China","award":["82573722"],"award-info":[{"award-number":["82573722"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Natural Science Foundation of Zhejiang Province","award":["2024-KYI-00I-I05"],"award-info":[{"award-number":["2024-KYI-00I-I05"]}]},{"name":"the Natural Science Foundation of Zhejiang Province","award":["LMS25H160019"],"award-info":[{"award-number":["LMS25H160019"]}]},{"name":"the Development Center for Medical Science and Technology National Health Commission of the People\u2019s Republic of China","award":["WKZX2024CX102213"],"award-info":[{"award-number":["WKZX2024CX102213"]}],"id":[{"id":"https:\/\/ror.org\/04bdenw41","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16518-w","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T01:42:46Z","timestamp":1783734166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of tertiary lymphoid structures in high-risk esophageal squamous cell carcinoma following neoadjuvant chemoimmunotherapy"],"prefix":"10.1186","volume":"26","author":[{"given":"Dongdong","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runzhou","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghua","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongshuo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4394-6176","authenticated-orcid":false,"given":"Haiping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"16518_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"B Freddie","year":"2024","unstructured":"Freddie B, Mathieu L, Hyuna S, Jacques F, Rebecca LS, Isabelle S, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"16518_CR2","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","volume":"381","author":"P Arjun","year":"2013","unstructured":"Arjun P, Michael KG, Blair AJ, James DL. Oesophageal carcinoma. Lancet. 2013;381:400\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(12)60643-6.","journal-title":"Lancet"},{"key":"16518_CR3","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"M Eileen","year":"2022","unstructured":"Eileen M, Isabelle S, Harriet R, Helen GC, Aaron PT, J\u00e9r\u00f4me V, et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology. 2022;163:649\u2013e6582. https:\/\/doi.org\/10.1053\/j.gastro.2022.05.054.","journal-title":"Gastroenterology"},{"key":"16518_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","volume":"21","author":"AA Jaffer","year":"2023","unstructured":"Jaffer AA, Thomas AD, David JB, David C, Carlos C, Prajnan D, et al. Esophageal and esophagogastric junction cancers, version 2.2023, NCCN Clinical Practice Guidelines in oncology. J Natl Compr Canc Netw. 2023;21:393\u2013422. https:\/\/doi.org\/10.6004\/jnccn.2023.0019.","journal-title":"J Natl Compr Canc Netw"},{"key":"16518_CR5","doi-asserted-by":"publisher","first-page":"e068714","DOI":"10.1136\/bmj-2021-068714","volume":"377","author":"L Zhihao","year":"2022","unstructured":"Zhihao L, Junye W, Yongqian S, Lianke L, Li K, Lei Y, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022;377:e068714. https:\/\/doi.org\/10.1136\/bmj-2021-068714.","journal-title":"BMJ"},{"key":"16518_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"D Yuichiro","year":"2022","unstructured":"Yuichiro D, Jaffer AA, Ken K, Jianming X, Lucjan W, Satoru M, et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med. 2022;386:449\u201362. https:\/\/doi.org\/10.1056\/NEJMoa2111380.","journal-title":"N Engl J Med"},{"key":"16518_CR7","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","volume":"326","author":"H Luo","year":"2021","unstructured":"Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021;326:916\u201325. https:\/\/doi.org\/10.1001\/jama.2021.12836.","journal-title":"JAMA"},{"key":"16518_CR8","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/s41416-022-01726-5","volume":"126","author":"M Tomoki","year":"2022","unstructured":"Tomoki M, Makoto Y, Koji T, Kotaro Y, Shinya U, Tomo I, et al. Multicenter randomised trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma. Br J Cancer. 2022;126:1555\u201362. https:\/\/doi.org\/10.1038\/s41416-022-01726-5.","journal-title":"Br J Cancer"},{"key":"16518_CR9","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1097\/SLA.0000000000004238","volume":"275","author":"H Takaomi","year":"2020","unstructured":"Takaomi H, Tomoki M, Makoto Y, Kotaro Y, Koji T, Takuro S, et al. Pathological regression of lymph nodes better predicts long-term survival in esophageal cancer patients undergoing neoadjuvant chemotherapy followed by surgery. Ann Surg. 2020;275:1121\u20139. https:\/\/doi.org\/10.1097\/SLA.0000000000004238.","journal-title":"Ann Surg"},{"key":"16518_CR10","doi-asserted-by":"publisher","first-page":"znaf004","DOI":"10.1093\/bjs\/znaf004","volume":"112","author":"Y Yang","year":"2025","unstructured":"Yang Y, Liu Z, Wong I, Gao X, Zhang H, Liu J, et al. Detecting residual disease after neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma: prospective multicentre preSINO trial. Br J Surg. 2025;112:znaf004. https:\/\/doi.org\/10.1093\/bjs\/znaf004.","journal-title":"Br J Surg"},{"key":"16518_CR11","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1002\/cam4.3783","volume":"10","author":"J Hyehyun","year":"2021","unstructured":"Hyehyun J, Hyeon-Su I, Yeonghak B, Yong-Hee K, Hyeong Ryul K, Hyun Joo L, et al. Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma. Cancer Med. 2021;10:1745\u201358. https:\/\/doi.org\/10.1002\/cam4.3783.","journal-title":"Cancer Med"},{"key":"16518_CR12","doi-asserted-by":"publisher","first-page":"7335","DOI":"10.1038\/s41467-021-27599-5","volume":"12","author":"QD Huy","year":"2021","unstructured":"Huy QD, Feng P, Geng W, Qingfeng H, Claire EO, Zhiyong W, et al. Integrated single-cell transcriptome analysis reveals heterogeneity of esophageal squamous cell carcinoma microenvironment. Nat Commun. 2021;12:7335. https:\/\/doi.org\/10.1038\/s41467-021-27599-5.","journal-title":"Nat Commun"},{"key":"16518_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12943-023-01731-z","volume":"22","author":"P Liping","year":"2023","unstructured":"Liping P, Yang L, Lin L, Shuochen G, Xueyan G, Yudi F, et al. Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1\/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22:29. https:\/\/doi.org\/10.1186\/s12943-023-01731-z.","journal-title":"Mol Cancer"},{"key":"16518_CR14","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1158\/2326-6066.CIR-18-0277","volume":"6","author":"AT Jonathan","year":"2018","unstructured":"Jonathan AT, Randy FS, Riyue B, Jason J. L. T cell\u2013inflamed versus non-T cell\u2013inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection. Cancer Immunol Res. 2018;6:990\u20131000. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0277.","journal-title":"Cancer Immunol Res"},{"key":"16518_CR15","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41419-023-06119-x","volume":"14","author":"F Jianwen","year":"2023","unstructured":"Jianwen F, Yue L, Jingyan Z, Xiaocong J, Haixing S, Xi S, et al. Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications. Cell Death Dis. 2023;14:586. https:\/\/doi.org\/10.1038\/s41419-023-06119-x.","journal-title":"Cell Death Dis"},{"key":"16518_CR16","doi-asserted-by":"publisher","first-page":"4916","DOI":"10.3390\/cancers13194916","volume":"13","author":"S Julie","year":"2021","unstructured":"Julie S, Di M, Tasmiah A, Jose Javier B-C. Remodeling the ECM: implications for metastasis and tumor dormancy. Cancers. 2021;13:4916. https:\/\/doi.org\/10.3390\/cancers13194916.","journal-title":"Cancers"},{"key":"16518_CR17","doi-asserted-by":"publisher","first-page":"eabf9419","DOI":"10.1126\/science.abf9419","volume":"375","author":"NS Ton","year":"2022","unstructured":"Ton NS, Daniela ST. Tertiary lymphoid structures in cancer. Science. 2022;375:eabf9419. https:\/\/doi.org\/10.1126\/science.abf9419.","journal-title":"Science"},{"key":"16518_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"S-F Catherine","year":"2019","unstructured":"Catherine S-F, Florent P, Julien C, Wolf Herman F. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19:307\u201325. https:\/\/doi.org\/10.1038\/s41568-019-0144-6.","journal-title":"Nat Rev Cancer"},{"key":"16518_CR19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"C Rita","year":"2020","unstructured":"Rita C, Martin L, Adriana S, Marco D, Mathilde SL, Shamik M, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577:561\u20135. https:\/\/doi.org\/10.1038\/s41586-019-1914-8.","journal-title":"Nature"},{"key":"16518_CR20","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3389\/fonc.2020.00980","volume":"10","author":"H Wenting","year":"2020","unstructured":"Wenting H, Dachuan Z, Hong L, Tongbing C, Jun X, Lei P, et al. The high level of tertiary lymphoid structure is correlated with superior survival in patients with advanced gastric cancer. Front Oncol. 2020;10:980. https:\/\/doi.org\/10.3389\/fonc.2020.00980.","journal-title":"Front Oncol"},{"key":"16518_CR21","doi-asserted-by":"publisher","first-page":"e70551","DOI":"10.1002\/cam4.70551","volume":"13","author":"L Yanfei","year":"2024","unstructured":"Yanfei L, Weiwei F, Wei X, Chao M, Xiuyun T, Chunyi H, et al. Prognostic value of N1\/N2 neutrophils heterogeneity and tertiary lymphoid structure in hepatocellular carcinoma patients. Cancer Med. 2024;13:e70551. https:\/\/doi.org\/10.1002\/cam4.70551.","journal-title":"Cancer Med"},{"key":"16518_CR22","doi-asserted-by":"publisher","unstructured":"Gabriela Sarti K, Glauco Akelinghton Freire V, Ariane Barros D, Mariela Pires C-P, Pedro Henrique Barbosa P, Maria C et al. Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas. Gut. 2023;72:1927\u201341. https:\/\/doi.org\/10.1136\/gutjnl-2022-328697.","DOI":"10.1136\/gutjnl-2022-328697"},{"key":"16518_CR23","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/cjp2.281","volume":"8","author":"L Rutao","year":"2022","unstructured":"Rutao L, Xing H, Wenmin Y, Jifan W, Yingkuan L, Te Z, et al. Tertiary lymphoid structures favor outcome in resected esophageal squamous cell carcinoma. J Pathol Clin Res. 2022;8:422\u201335. https:\/\/doi.org\/10.1002\/cjp2.281.","journal-title":"J Pathol Clin Res"},{"key":"16518_CR24","doi-asserted-by":"publisher","first-page":"e1074","DOI":"10.1002\/ctm2.1074","volume":"12","author":"L Yihong","year":"2022","unstructured":"Yihong L, Jian Z, Zelin W, Guangrong L, Caixia L, Chuqing P, et al. The prognostic value and molecular properties of tertiary lymphoid structures in oesophageal squamous cell carcinoma. Clin Transl Med. 2022;12:e1074. https:\/\/doi.org\/10.1002\/ctm2.1074.","journal-title":"Clin Transl Med"},{"key":"16518_CR25","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.3390\/cancers17203351","volume":"17","author":"K Tomoyoshi","year":"2025","unstructured":"Tomoyoshi K, Kazuhiro N, Noriyuki N, Seitaro N, Yasushige T, Hijiri M, et al. Tertiary lymphoid structures are associated with favorable clinical outcomes and negatively correlated with cancer-associated fibroblasts in esophageal cancer. Cancers (Basel). 2025;17:3351. https:\/\/doi.org\/10.3390\/cancers17203351.","journal-title":"Cancers (Basel)"},{"key":"16518_CR26","doi-asserted-by":"publisher","first-page":"e005531","DOI":"10.1136\/jitc-2022-005531","volume":"10","author":"S Xiaoyan","year":"2022","unstructured":"Xiaoyan S, Weiran L, Leina S, Huilan M, Yingnan F, Xinyi W, et al. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2022;10:e005531. https:\/\/doi.org\/10.1136\/jitc-2022-005531.","journal-title":"J Immunother Cancer"},{"key":"16518_CR27","doi-asserted-by":"publisher","first-page":"1616247","DOI":"10.3389\/fimmu.2025.1616247","volume":"16","author":"Z Ke","year":"2025","unstructured":"Ke Z, Ru X, Kun R, Miaoqing Z. Tertiary lymphoid structures correlate with the therapeutic efficacy and prognosis of resectable esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy plus immunotherapy. Front Immunol. 2025;16:1616247. https:\/\/doi.org\/10.3389\/fimmu.2025.1616247.","journal-title":"Front Immunol"},{"key":"16518_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41698-024-00579-w","volume":"8","author":"C Ziqiang","year":"2024","unstructured":"Ziqiang C, Wang X, Jin Z, Li B, Jiang D, Wang Y, et al. Deep learning on tertiary lymphoid structures in hematoxylin-eosin predicts cancer prognosis and immunotherapy response. NPJ Precis Oncol. 2024;8:73. https:\/\/doi.org\/10.1038\/s41698-024-00579-w.","journal-title":"NPJ Precis Oncol"},{"key":"16518_CR29","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1158\/0008-5472.CAN-17-1987","volume":"78","author":"S Kar\u012bna","year":"2018","unstructured":"Kar\u012bna S, Alex S, Farkhondeh MA, Ruben C, Zina MU, Helen T, et al. Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. Cancer Res. 2018;78:1308\u201320. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1987.","journal-title":"Cancer Res"},{"key":"16518_CR30","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.ccell.2024.07.006","volume":"42","author":"Z Yifan","year":"2024","unstructured":"Yifan Z, Guangjian L, Qianwen Z, Wenrui W, Kai L, Chuankai Z, et al. CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis. Cancer Cell. 2024;42:1370\u2013e13859. https:\/\/doi.org\/10.1016\/j.ccell.2024.07.006.","journal-title":"Cancer Cell"},{"key":"16518_CR31","doi-asserted-by":"publisher","first-page":"e009232","DOI":"10.1136\/jitc-2024-009232","volume":"12","author":"Z Yuanyuan","year":"2024","unstructured":"Yuanyuan Z, Zhen F, Baorui T, Zunguo D, Zhifeng S. Density of tertiary lymphoid structures predicts clinical outcome in breast cancer brain metastasis. J Immunother Cancer. 2024;12:e009232. https:\/\/doi.org\/10.1136\/jitc-2024-009232.","journal-title":"J Immunother Cancer"},{"key":"16518_CR32","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1001\/jama.2024.3056","volume":"331","author":"AL-F Roberto","year":"2024","unstructured":"Roberto AL-F, Sarah Flora J, Roberto S, Sherene L, Vicent de J, Jodi MC, et al. Tumor-Infiltrating lymphocytes in triple-negative breast cancer. JAMA. 2024;331:1135\u201344. https:\/\/doi.org\/10.1001\/jama.2024.3056.","journal-title":"JAMA"},{"key":"16518_CR33","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41587-020-0472-9","volume":"38","author":"RM Christopher","year":"2020","unstructured":"Christopher RM, Giang T, O, Sarah EC, Kristi B, Patrick D, Gary G, et al. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat Biotechnol. 2020;38:586\u201399. https:\/\/doi.org\/10.1038\/s41587-020-0472-9.","journal-title":"Nat Biotechnol"},{"key":"16518_CR34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.5114\/pjp.2021.115662","volume":"73","author":"K-R Marta","year":"2022","unstructured":"Marta K-R, Beata B, Dorota S, Anna M-M. Nanog expression in patients with squamous cell carcinoma of oropharynx in relation to immunohistochemical score. Pol J Pathol. 2022;73:60\u201371. https:\/\/doi.org\/10.5114\/pjp.2021.115662.","journal-title":"Pol J Pathol"},{"key":"16518_CR35","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.bbrc.2022.10.016","volume":"634","author":"AL Jessica","year":"2022","unstructured":"Jessica AL, Lauren AG, Julie KJ, Alan LE, Frank H, Jean C. Deletion of monoamine oxidase A in a prostate cancer model enhances anti-tumor immunity through reduced immune suppression. Biochem Biophys Res Commun. 2022;634:100\u20137. https:\/\/doi.org\/10.1016\/j.bbrc.2022.10.016.","journal-title":"Biochem Biophys Res Commun"},{"key":"16518_CR36","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1038\/s41467-021-23164-2","volume":"12","author":"W Yu-Chen","year":"2021","unstructured":"Yu-Chen W, Xi W, Jiaji Y, Feiyang M, Zhe L, Yang Z, et al. Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy. Nat Commun. 2021;12:3530. https:\/\/doi.org\/10.1038\/s41467-021-23164-2.","journal-title":"Nat Commun"},{"key":"16518_CR37","doi-asserted-by":"publisher","first-page":"e005531","DOI":"10.1136\/jitc-2022-005531","volume":"10","author":"S Xiaoyan","year":"2022","unstructured":"Xiaoyan S, Weiran L, Leina S, Huilan M, Yingnan F, Xinyi W, et al. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2022;10:e005531. https:\/\/doi.org\/10.1136\/jitc-2022-005531.","journal-title":"J Immunother Cancer"},{"key":"16518_CR38","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1186\/s12885-022-09777-w","volume":"22","author":"D Sota","year":"2022","unstructured":"Sota D, Hiroaki T, Shugo S, Seji N, Takuya M, Yuichiro M, et al. Clinical relevance of tertiary lymphoid structures in esophageal squamous cell carcinoma. BMC Cancer. 2022;22:699. https:\/\/doi.org\/10.1186\/s12885-022-09777-w.","journal-title":"BMC Cancer"},{"key":"16518_CR39","doi-asserted-by":"publisher","first-page":"217178","DOI":"10.1016\/j.canlet.2024.217178","volume":"601","author":"H Hui","year":"2024","unstructured":"Hui H, Gang Z, Tierun W, Yi Y, Tian Z, Xi C, et al. Survival benefit and spatial properties of tertiary lymphoid structures in esophageal squamous cell carcinoma with neoadjuvant therapies. Cancer Lett. 2024;601:217178. https:\/\/doi.org\/10.1016\/j.canlet.2024.217178.","journal-title":"Cancer Lett"},{"key":"16518_CR40","doi-asserted-by":"publisher","first-page":"1606499","DOI":"10.3389\/fimmu.2025.1606499","volume":"16","author":"Z Chengjuan","year":"2025","unstructured":"Chengjuan Z, Ruihua B, Yanping H, Tao W, Bin M, Junxia Z, et al. Heterogeneity and distribution characteristics of tertiary lymphoid structures predict prognostic outcome in esophageal squamous cell carcinoma. Front Immunol. 2025;16:1606499. https:\/\/doi.org\/10.3389\/fimmu.2025.1606499.","journal-title":"Front Immunol"},{"key":"16518_CR41","doi-asserted-by":"publisher","first-page":"e006425","DOI":"10.1136\/jitc-2022-006425","volume":"11","author":"Z Chong","year":"2023","unstructured":"Chong Z, Xiangyu W, Jieliang Z, Xuefu W, Xiaowen F, Bo Z, et al. Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases. J Immunother Cancer. 2023;11:e006425. https:\/\/doi.org\/10.1136\/jitc-2022-006425.","journal-title":"J Immunother Cancer"},{"key":"16518_CR42","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jhep.2021.10.030","volume":"76","author":"D Guangyu","year":"2022","unstructured":"Guangyu D, Jiaqiang M, Jingping Y, Xing C, Yu L, Shu Z, et al. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. J Hepatol. 2022;76:608\u201318. https:\/\/doi.org\/10.1016\/j.jhep.2021.10.030.","journal-title":"J Hepatol"},{"key":"16518_CR43","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1038\/s41416-023-02235-9","volume":"128","author":"H Yoshinori","year":"2023","unstructured":"Yoshinori H, Tomoki M, Eiichi S, Kenji O, Yuya N, Takashi K, et al. Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors. Br J Cancer. 2023;128:2175\u201385. https:\/\/doi.org\/10.1038\/s41416-023-02235-9.","journal-title":"Br J Cancer"},{"key":"16518_CR44","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.3889\/oamjms.2018.341","volume":"6","author":"T Gjorgji","year":"2018","unstructured":"Gjorgji T, Ljubomir O, Zoran K, Gjorgji J, Dragan H-M, Ognen K, et al. Tertiary lymphoid structures in colorectal cancers and their prognostic value. Open Access Maced J Med Sci. 2018;6:1824\u20138. https:\/\/doi.org\/10.3889\/oamjms.2018.341.","journal-title":"Open Access Maced J Med Sci"},{"key":"16518_CR45","doi-asserted-by":"publisher","first-page":"962056","DOI":"10.3389\/fimmu.2022.962056","volume":"13","author":"W Qianyu","year":"2022","unstructured":"Qianyu W, Xiaofei S, Ran A, Junchao B, Junhua D, Huiyun C, et al. Peritumoral tertiary lymphoid structure and tumor stroma percentage predict the prognosis of patients with non-metastatic colorectal cancer. Front Immunol. 2022;13:962056. https:\/\/doi.org\/10.3389\/fimmu.2022.962056.","journal-title":"Front Immunol"},{"key":"16518_CR46","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00262-025-03952-1","volume":"74","author":"X Shuai","year":"2025","unstructured":"Shuai X, Chao H, Jian Z, Di Y, Hui D, Yiwei Z, et al. Distinct maturity and spatial distribution of tertiary lymphoid structures in head and neck squamous cell carcinoma: implications for tumor immunity and clinical outcomes. Cancer Immunol Immunother. 2025;74:107. https:\/\/doi.org\/10.1007\/s00262-025-03952-1.","journal-title":"Cancer Immunol Immunother"},{"key":"16518_CR47","doi-asserted-by":"publisher","first-page":"1390938","DOI":"10.3389\/fimmu.2024.1390938","volume":"15","author":"H Lingbo","year":"2024","unstructured":"Lingbo H, Xuemei L, Changhong Y, Baoyong Z, Chengyou D, Ning J. Prognostic value of tertiary lymphoid structures in hepatocellular carcinoma: a meta-analysis and systematic review. Front Immunol. 2024;15:1390938. https:\/\/doi.org\/10.3389\/fimmu.2024.1390938.","journal-title":"Front Immunol"},{"key":"16518_CR48","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00262-022-03353-8","volume":"72","author":"W Sho","year":"2023","unstructured":"Sho W, Tetsuzo T, Naoki H, Fumihiko K, Yuka O, Yuki O, et al. Preventive effect of tertiary lymphoid structures on lymph node metastasis of lung adenocarcinoma. Cancer Immunol Immunother. 2023;72:1823\u201334. https:\/\/doi.org\/10.1007\/s00262-022-03353-8.","journal-title":"Cancer Immunol Immunother"},{"key":"16518_CR49","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10549-020-05548-y","volume":"180","author":"S Dominique Yuan Bin","year":"2020","unstructured":"Dominique Yuan Bin S, Joe Poh Sheng Y, Johnathan Xiande L, Noel C, Jeffrey Chun Tatt L, Clara Chong Hui O, et al. Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers. Breast Cancer Res Treat. 2020;180:369\u201377. https:\/\/doi.org\/10.1007\/s10549-020-05548-y.","journal-title":"Breast Cancer Res Treat"},{"key":"16518_CR50","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-15-2762","volume":"22","author":"DRK Katy","year":"2016","unstructured":"Katy DRK, Brad M. Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer. Clin Cancer Res. 2016;22:3005\u201315. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2762.","journal-title":"Clin Cancer Res"},{"key":"16518_CR51","doi-asserted-by":"publisher","first-page":"106030","DOI":"10.1016\/j.ebiom.2025.106030","volume":"122","author":"T Na","year":"2025","unstructured":"Na T, Qianyu W, Yuan L, Wentao Z, Weixuan L, Huiyun C, et al. Mature tertiary lymphoid structures support B cell-mediated antitumour immunity and are disrupted by neoadjuvant therapy in rectal cancer: a multicentre, retrospective study. eBioMedicine. 2025;122:106030. https:\/\/doi.org\/10.1016\/j.ebiom.2025.106030.","journal-title":"eBioMedicine"},{"key":"16518_CR52","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1016\/j.immuni.2025.09.018","volume":"58","author":"C Pinar","year":"2025","unstructured":"Pinar C, Jennifer HL, Aakanksha S, Jadranka M, Jonathan S, Jonas S, et al. Spatial immune profiling defines a subset of human gliomas with functional tertiary lymphoid structures. Immunity. 2025;58:2847\u2013e28638. https:\/\/doi.org\/10.1016\/j.immuni.2025.09.018.","journal-title":"Immunity"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16518-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16518-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16518-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:31:48Z","timestamp":1791243108000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16518-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16518"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16518-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9957620\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"7 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The research was approved by the Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine (Hangzhou, China) (No. 2024\u2009\u2212\u20091147). Written informed consent was obtained from all participants involved in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1192"}}